格列美脲与二甲双胍联合利拉鲁肽改善2型糖尿病血糖、血脂的临床研究

Clinical Study of Glimepiride and Metformin Combined with Liraglutide on Improving Blood Glucose and Lipids in Patients with Type 2 Diabetes

目的:探讨格列美脲与二甲双胍联合利拉鲁肽对2型糖尿病血糖、血脂的临床疗效。方法:选取2019年1月-2020年10月在本院治疗的2型糖尿病(T2DM)患者100例,采用数字表法将其分成对照组与研究组,各50例,给予对照组格列美脲与二甲双胍治疗,在对照组的治疗基础上,给予研究组利拉鲁肽治疗,对比两组入选对象的疗效及治疗前后血糖水平和相关血脂指标。结果:治疗前两组患者的血糖指标比较均无统计学意义(P>0.05),治疗后研究组餐后2 h血糖(2 h PG)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)等指标均低于对照组(P<0.05)。治疗前两组血脂指标水平比较差异无统计学意义(P>0.05),治疗后研究组的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)等指标显著低于对照组(P<0.05),而高密度脂蛋白胆固醇(HDL-C)指标显著高于对照组(P<0.05)。研究组治疗有效率显著高于对照组(P<0.05)。结论:格列美脲与二甲双胍联合利拉鲁肽治疗T2DM患者,具有很好的效果,不仅有效降低了患者血糖水平,而且还对血脂水平的调节起到一定的促进作用,值得在临床上推荐使用。

Objective:To investigate the clinical effect of Glimepiride and Metformin combined with Liraglutide on improving blood glucose and blood lipid in type 2 diabetes.Method:A total of 100 patients with type 2 diabetes mellitus(T2DM)who were treated in our hospital from January 2019 to October 2020 were divided into the control group(50 cases)and the study group(50 cases).The control group was treated with Glimepiride and Metformin,the study group received Liraglutide treatment on the basic of the control group.The treatment efficacy,blood glucose levels and related lipid indicators before and after treatment between the two groups were compared.Result:There were no significant differences in blood glucose indicators between the two groups before treatment(P>0.05),after treatment,the postprandial 2-hour blood glucose(2 h PG),fasting blood glucose(FPG)and glycated hemoglobin(HbA1c)in the study group were lower than those in the control group(P<0.05).There were no significant differences in related lipid indicators between the two groups before treatment(P>0.05),after treatment,the total cholesterol(TC),triglyceride cholesterol(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)in the study group were significantly lower than those in the control group(P<0.05).The therapeutic effect rate of the study group was significantly higher than that of the control group(P<0.05),Conclusion:The combination of Glimepiride and Metformin with Liraglutide is effective in the treatment of T2DM patients.It not only effectively reduces the blood glucose level,but also promotes the regulation of blood lipid level,it is worth recommending in clinical use.